This article presents a well-documented case report accompanied by a concise literature review, focusing on the safety of secukinumab use during pregnancy in a patient with severe plaque psoriasis. Psoriasis is a chronic immune-mediated inflammatory disease that disproportionately affects women of childbearing age, yet therapeutic options during pregnancy remain limited due to concerns regarding fetal safety. Biologic agents such as secukinumab (an IL-17A inhibitor) have demonstrated excellent efficacy in moderate-to-severe psoriasis, but clinical evidence supporting their use during pregnancy is scarce.

The reported case involves a 27-year-old woman with long-standing, treatment-refractory severe plaque psoriasis who achieved rapid and substantial disease control following secukinumab therapy. An unplanned pregnancy was discovered at five weeks of gestation, prompting immediate discontinuation of the biologic. Despite early pregnancy exposure, the patient experienced no pregnancy-related complications, including gestational diabetes, hypertension, preeclampsia, preterm birth, or cesarean delivery. She delivered a healthy full-term male infant with normal birth weight. Importantly, long-term follow-up extending to 2.5 years postpartum demonstrated normal physical growth, laboratory parameters, and developmental milestones in the child. The mother also maintained good disease control postpartum after resuming secukinumab, highlighting its sustained efficacy and tolerability.

By integrating this case with previously published reports, the authors provide additional real-world evidence suggesting that secukinumab exposure during early pregnancy may not be associated with adverse maternal or fetal outcomes. Although limited by the inherent nature of case reports, this study contributes valuable safety data to an area where prospective trials are ethically and practically challenging. Overall, the findings support cautious optimism regarding the use of secukinumab in selected pregnant patients with severe psoriasis when therapeutic benefits outweigh potential risks, while emphasizing the need for further data from larger cohorts and pregnancy registries.